Weekly Docetaxel as Second-line Chemotherapy in Advanced Non-small Cell Lung Cancer: Phase II Trial

Anticancer Research

Volumn 24, Issue 2 C, 2004, Pages 1211-1216

  Serke, Monika ^a   Schoenfeld, Nikolas ^a   Loddenkemper, Robert ^a  

^a Zentralklinik Emil von Behring   (Germany)

Author keywords

Chemotherapy; Docetaxel; Non small cell lung cancer; Second line; Taxane

Indexed keywords

DOCETAXEL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON DIVERTICULOSIS; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG TOLERANCE; DYSPNEA; ESOPHAGITIS; FEMALE; FEVER; FLUID RETENTION; GRANULOCYTOPENIA; HEADACHE; HEART ARRHYTHMIA; HEMATOCHEZIA; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MOTOR DYSFUNCTION; NAUSEA; NEPHROTOXICITY; PNEUMOTHORAX; POLYNEUROPATHY; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; STOMATITIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SALVAGE THERAPY; TAXOIDS;

EID: 2442510088     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15: 2996-3018, 1997.
2. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899-909, 1995.
3. Schiller JH, Harrington D, Sandler A et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002.
4. Shepherd FA: Chemotherapy for non-small cell lung cancer. Have we reached a new plateau? Semin Oncol 26: 3-11, 1999.
5. Fossella FV, Lee JS and Hong WK: Management strategies for recurrent non-small cell lung cancer. Semin Oncol 24: 455-462, 1997.
6. Fossella FV, Lee JS, Shin DM et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 13: 645-651, 1995.
7. Le Chevalier T: Docetaxel: meeting the challenge of non-small cell lung cancer management. Anticancer Drugs 6: 13-17, 1995.
8. Yokoyama A, Kurita Y and Watanabe K: Early phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer: Docetaxel Cooperative Study Group for Lung Cancer. Gan To Kagaku Ryoho 21: 2609-2626, 1994 (Japanese).
9. Shepherd FA, Dancey J, Ramlau R et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000.
10. Fossella FV, DeVore R, Kerr RN et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18: 2354-2362, 2000.
11. Kamen BA, Rubin E, Aisner J and Glatstein E: High-time chemotherapy or high time for low dose. J Clin Oncol 18: 2935-2937, 2000.
12. Hainsworth JD, Burris HA, Erland JB et al: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16: 2164-2168, 1998.
13. Miller AB, Hoogstraten B, Staquet M et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
14. Gomez RG, Perez-Segura P, Mendez M et al: A phase II study of weekly docetaxel in previously treated patients with non-small cell lung cancer (NSCLC) (abstract 2818). Proc Am Soc Clin Oncol 20: 267b, 2001.
15. Lilenbaum, RC, Schwartz, MA, Seigel L et al: Phase II trial of weekly docetaxel in second-line therapy for non-small cell lung carcinoma: Cancer 92: 2158-2163, 2001.
16. Lin C: Phase II study of weekly docetaxel as second-line chemotherapy in patients with unresectable or metastatic non-small cell lung cancer (abstract 2853). Proc Am Soc Clin Oncol 20: 275b, 2001.
17. Petrioli R, Pozzessere D, Messinese S et al: Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens. Lung Cancer 39: 85-89, 2003.
18. Valerio MR, Russo A, Latteri MA et al: Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis. Lung Cancer 34 (Suppl. 4): S31-S35, 2001.
19. Schütte W, Nagel S, Lautenschläger C, Wollschläger B and Serke M: Randomized phase III study of weekly versus three-weekly docetaxel as second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) (abstract 1228). Proc Am Soc Clin Oncol 21: 308a, 2002.
20. Hainsworth JD, Burris HA, Litchy S et al: Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. Cancer 89: 328-333, 2000.